See more : va-Q-tec AG (VQT.DE) Income Statement Analysis – Financial Results
Complete financial analysis of TCR2 Therapeutics Inc. (TCRR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TCR2 Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- River and Mercantile Group PLC (RIV.L) Income Statement Analysis – Financial Results
- Hainan Development Holdings Nanhai Co., Ltd. (002163.SZ) Income Statement Analysis – Financial Results
- Caisse Régionale de Crédit Agricole Mutuel du Languedoc Société coopérative (CRLA.PA) Income Statement Analysis – Financial Results
- Hapbee Technologies, Inc. (HAPBF) Income Statement Analysis – Financial Results
- Electricity Generating Public Company Limited (ECGF.F) Income Statement Analysis – Financial Results
TCR2 Therapeutics Inc. (TCRR)
About TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.64M | 77.24M | 51.98M | 37.49M | 19.67M | 9.57M | 7.67M |
| General & Administrative | 24.44M | 22.50M | 16.72M | 13.89M | 6.78M | 3.61M | 2.26M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.44M | 22.50M | 16.72M | 13.89M | 6.78M | 3.61M | 2.26M |
| Other Expenses | 30.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 123.08M | 99.74M | 68.70M | 51.38M | 26.45M | 13.18M | 9.93M |
| Cost & Expenses | 123.08M | 99.74M | 68.70M | 51.38M | 26.45M | 13.18M | 9.93M |
| Interest Income | 1.94M | 224.00K | 1.74M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 58.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 63.88M | 2.83M | 1.59M | 862.00K | 419.00K | 298.00K | 220.00K |
| EBITDA | -89.62M | -96.92M | -67.11M | -50.52M | -23.83M | -12.77M | -9.70M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -153.50M | -99.74M | -68.70M | -51.38M | -26.45M | -13.18M | -9.93M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.94M | 224.00K | 1.74M | 3.89M | 2.20M | 110.00K | 15.00K |
| Income Before Tax | -151.56M | -99.52M | -66.96M | -47.50M | -24.25M | -13.07M | -9.92M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 261.00K | 289.00K | 161.00K | 102.00K | 2.20M | 110.00K | 15.00K |
| Net Income | -151.82M | -99.81M | -67.12M | -47.60M | -24.25M | -13.07M | -9.92M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.93 | -2.63 | -2.40 | -2.26 | -1.05 | -2.55 | -1.93 |
| EPS Diluted | -3.93 | -2.63 | -2.40 | -2.26 | -1.05 | -2.55 | -1.93 |
| Weighted Avg Shares Out | 38.63M | 37.94M | 27.99M | 21.10M | 23.19M | 5.13M | 5.13M |
| Weighted Avg Shares Out (Dil) | 38.63M | 37.94M | 27.99M | 21.10M | 23.19M | 5.13M | 5.13M |
TCR² Therapeutics to Present at the Needham Healthcare Conference
TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline
TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock
TCR² Therapeutics Announces Proposed Public Offering of Common Stock
TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones
TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors
TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors
Source: https://incomestatements.info
Category: Stock Reports